

Review Form 1.7

Journal Name:	Asian Journal of Immunology
Manuscript Number:	Ms_AJI_102727
Title of the Manuscript:	TOFACITINIB FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS IN ADULTS - RECENT INSIGHTS
Type of the Article	Review Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journalaji.com/index.php/AJI/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <ol style="list-style-type: none"> 1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript) 2. Is the title of the article suitable? (If not please suggest an alternative title) 3. Is the abstract of the article comprehensive? 4. Are subsections and structure of the manuscript appropriate? 5. Do you think the manuscript is scientifically correct? 6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form. <p>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</p>	<p>Immunotherapy is explosive in modern medicine. The objective of this article is greatly important.</p> <p>Acceptable</p> <p>Acceptable</p> <p>Acceptable</p> <p>Acceptable</p> <p>Fairly acceptable after addition of recent references</p>	
<p>Minor REVISION comments</p> <ol style="list-style-type: none"> 1. Is language/English quality of the article suitable for scholarly communications? 	<p>English need to be improved</p>	
<p>Optional/General comments</p>	<p>The word used in Conclusion "ORAL Surveillance research" should be explained for a better understanding.</p> <p>In Introduction : "This affects signalling via IL-17, IL-21 and IL-23, which have been implicated in AS pathology[19-21]"; Please check these three references describe and discuss the pathology of AS or implication of these interleukins in AS pathogenesis.</p>	

[Review Form 1.7](#)

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Ne Win
Department, University & Country	University of Medicine, Myanmar